New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2015
07:14 EDTNLNKNewLink Genetics price target raised to $62 from $44 at Cantor
Cantor increased its price target on NewLink, citing positive developments at the company's Investor Day, including an estimated median OS assumption for the IMPRESS trial, new clinical programs and potential data this year from the company's indoximod and IDO/TDO programs. The firm thinks the company sits in a virtual "sweet spot" of oncology drug development and reiterates a Buy rating.
06:03 EDTNLNKNewLink Genetics price target raised to $62 from $50 at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use